Concepedia

Author

Olivier Vitse

Sanofi (United States)ORCID

Also Known As

O Vitse, O. VITSE, O. Vitse, Olivier Vitse

20

Publications

161

Citations

8

H-Index

11

Concepts

All Affiliations

Sanofi (United States)Sanofi (France)AVEO Oncology (United States)
OV

About

Olivier Vitse is an author at Sanofi (United States) specializing in pharmacotherapy, natural sciences, and engineering.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Engineering

1

1

11

2

Medicine

1

1

28

3

Natural Sciences

1

1

28

4

Biochemistry

1

1

28

5

Chemical Biology

1

1

28

Olivier Vitse

×

5

Publications

108

Citations

5

H-Index

YearCitations

Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease

Mazen M. Dimachkie, Richard J. Barohn, Barry J. Byrne,

Neurology

2022

42

New imidazo[1,2-a]pyrazine derivatives with bronchodilatory and cyclic nucleotide phosphodiesterase inhibitory activities

Olivier Vitse, Florence Laurent, Tristan Pocock,

Bioorganic & Medicinal Chemistry

1999

28

First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection

L. Bergougnan, Sara Armani, Georg Golor,

British Journal of Clinical Pharmacology

2020

14

Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial

L. Bergougnan, Grit Andersen, Leona Plum‐Mörschel,

British Journal of Clinical Pharmacology

2020

13

Aza-indolizine with bridgehead nitrogen. Metalation, halogen-metal exchange and directed ortho-lithiation in the imidazo[1,2-a]pyrazine series

Olivier Vitse, Jacques Bompart, Guy Subra,

Tetrahedron

1998

11

Page 1